Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)
Today, Credit Suisse Group reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ:ALXN) with a price target of $147.00.
Some recent analyst ratings include
- 1/18/2018-Credit Suisse Group Reiterated Rating of Buy.
- 1/4/2018-Raymond James Financial Reiterated Rating of Strong-Buy .
- 12/18/2017-Robert W. Baird Upgrade from a “Neutral ” rating to a ” Outperform” rating.
- 12/6/2017-Leerink Swann Reiterated Rating of Buy.
- 10/23/2017-Piper Jaffray Companies Reiterated Rating of Overweight .
Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.35% and institutional ownership of 94.27%.
- On 1/2/2018 Ludwig Hantson, CEO, sold 2,553 with an average share price of $121.63 per share and the total transaction amounting to $310,521.39.
- On 10/2/2017 Heidi L Wagner, SVP, sold 120 with an average share price of $140.00 per share and the total transaction amounting to $16,800.00.
- On 9/5/2017 Ann M Veneman, Director, sold 835 with an average share price of $145.81 per share and the total transaction amounting to $121,751.35.
- On 9/5/2017 Julie O’neill, EVP, sold 4,375 with an average share price of $145.44 per share and the total transaction amounting to $636,300.00.
- On 8/28/2017 Julie O’neill, EVP, sold 11,160 with an average share price of $140.00 per share and the total transaction amounting to $1,562,400.00.
- On 7/31/2017 Ann M Veneman, Director, sold 700 with an average share price of $137.74 per share and the total transaction amounting to $96,418.00.
- On 6/15/2017 Bros. Advisors Lp Baker, Director, bought 660,779 with an average share price of $117.33 per share and the total transaction amounting to $77,529,200.07.
Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at with 185177 shares trading hands.